Caspofungin

Generic Name: Caspofungin

Brand Names: Cancidas, Cancidas (previously Caspofungin MSD)

Drug Type: Small Molecule

Chemical Formula: C_₅₂H_₈₈N_₁₀O_₁₅

CAS Number: 162808-62-0

Unique Ingredient Identifier: F0XDI6ZL63

Background: Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.

Indication: For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Associated Conditions: Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Oropharyngeal Candidiasis, Peritonitis, Pleural space infections

Associated Therapies: -

Clinical Trials

Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients

Not Applicable

Conditions: Pneumocystis Pneumonia

Interventions: Drug: Sulfanilamides
Drug: caspofungin
Drug: corticosteroids

First Posted Date: 2015-11-13

Last Posted Date: 2020-03-13

Lead Sponsor: Beijing Chao Yang Hospital

Target Recruit Count: 60

Registration Number: NCT02603575

Locations: 🇨🇳
Beijing Chao Yang Hospital, Beijing, China

Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients

Not Applicable

Completed

Conditions: Shock

Interventions: Drug: Caspofungin

First Posted Date: 2015-11-04

Last Posted Date: 2019-06-14

Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Target Recruit Count: 50

Registration Number: NCT02596984

Locations: 🇫🇷
CHU de CLERMONT-FERRAND, Clermont-ferrand, France
🇫🇷
Hôpital Saint-Louis, Paris, France
🇫🇷
CHU de SAINT-ETIENNE, Saint-etienne, France

Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit

Not Applicable

Conditions: Invasive Fungal Infection

Interventions: Drug: Caspofungin

First Posted Date: 2015-07-28

Last Posted Date: 2015-07-28

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 40

Registration Number: NCT02510053

Optimal Dosage of Caspofungin in Critically Ill Patients

Phase 4

Completed

Conditions: Suspected Invasive Candidiasis
Critically Ill

Interventions: Drug: Caspofungin

First Posted Date: 2013-11-25

Last Posted Date: 2015-10-30

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 20

Registration Number: NCT01994096

Locations: 🇳🇱
University Medical Centre Groningen, Groningen, Netherlands

Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Phase 2

Terminated

Conditions: Candidiasis, Invasive

Interventions: Drug: Caspofungin
Drug: Amphotericin B Deoxycholate

First Posted Date: 2013-09-18

Last Posted Date: 2019-11-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 51

Registration Number: NCT01945281

Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates

Completed

Conditions: Invasive Fungal Infection

Interventions: Drug: caspofungin

First Posted Date: 2012-02-15

Last Posted Date: 2020-12-01

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 20

Registration Number: NCT01533558

Locations: 🇳🇱
Canisius Wilhelmina Hospital (CWZ), Nijmegen, Netherlands
🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
🇳🇱
University Medical Centre Utrecht, Utrecht, Netherlands

and more 1 locations

Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease

Phase 4

Conditions: Invasive Pulmonary Aspergillosis
Chronic Obstructive Pulmonary Disease

Interventions: Drug: caspofungin

First Posted Date: 2011-12-26

Last Posted Date: 2014-01-23

Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University

Target Recruit Count: 40

Registration Number: NCT01499433

Locations: 🇨🇳
Guangzhou Institute of Respiratory Diseases, Guangzhou, Guangdong, China

Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis

Phase 2

Completed

Conditions: Fungal Infection

Interventions: Drug: caspofungin

First Posted Date: 2011-03-18

Last Posted Date: 2014-01-09

Lead Sponsor: Werner J. Heinz

Target Recruit Count: 25

Registration Number: NCT01318148

Locations: 🇩🇪
University of Wuerzburg Medical Centre, Department of Internal Medicine II, Wuerzburg, Germany

Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients

Phase 2

Conditions: Fungemia
Mycoses

Interventions: Drug: Caspofungin

First Posted Date: 2010-12-16

Last Posted Date: 2012-07-18

Lead Sponsor: Azienda Ospedaliera di Padova

Target Recruit Count: 38

Registration Number: NCT01260974

Locations: 🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

Phase 2

Completed

Conditions: Aspergillosis
Candidiasis, Invasive
Candidiasis, Esophageal

Interventions: Drug: Caspofungin

First Posted Date: 2010-07-19

Last Posted Date: 2018-08-27

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 20

Registration Number: NCT01165320

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy